Skip to main content

Advertisement

SpringerLink
Log in

Liposomal itraconazole formulation for the treatment of glioblastoma using inclusion complex with HP-β-CD

  • Original Article
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

Purpose

Itraconazole, which has been widely used as an antifungal-agent, is revisited as an anticancer drug but its low solubility still remains a major hurdle.

Methods

Inclusion complex was used to enhance the solubility of itraconazole, followed by encapsulating into liposome for glioblastoma.

Results

Itraconazole-inclusion complex was well formed at 1:1, 1:2 and 1:3 molar ratios of itraconazole: hydroxypropyl-β-cyclodextrin (HP-β-CD) as determined by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and Fourier transform infrared spectroscopy (FT-IR) analyses. Itraconazole-HP-β-CD inclusion complex was then encapsulated in liposome and its size was 120.5 ± 53.1 nm in diameter with 50% encapsulation efficiency. Stem cell-like property, as determined by the population ratio of CD90+/CD133+, was decreased from 3.38 to 1.46% when the U87-MG-TL cells were treated with 100 µM itraconazole/HP-β-CD-loaded liposome. Anti-proliferative effect of itraconazole/HP-β-CD-loaded liposome on U87-MG-TL cells was slightly better than that of free itraconazole (IC50 of 17 µM vs. 26 µM). Moreover, anti-proliferative effect of Itraconazole/HP-β-CD-loaded liposome on U87-MG-TL cells was higher than that of free itraconazole when the cells were co-treated with temozolomide (IC50 of 1.58 mM vs. 2.35 mM).

Conclusions

Therefore, itraconazole/HP-β-CD-loaded liposomal formulation could serve as a promising strategy for targeting the glioblastoma multiforme.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Cevc G (2012) Rational design of new product candidates: the next generation of highly deformable bilayer vesicles for noninvasive, targeted therapy. J Control Release 160:135–146

    Article  CAS  PubMed  Google Scholar 

  • Gharib R, Greige-Gerges H, Fourmentin S, Charcosset C, Auezova L (2015) Liposomes incorporating cyclodextrin–drug inclusion complexes: current state of knowledge. Carbohydr Polym 129:175–186

    Article  CAS  PubMed  Google Scholar 

  • Ghorab MK, Adeyeye MC (2001) Enhancement of ibuprofen dissolution via wet granulation with beta-cyclodextrin. Pharm Dev Technol 6:305–314

    Article  CAS  PubMed  Google Scholar 

  • Gil A, Chamayou A, Leverd E, Bougaret J, Baron M et al (2004) Evolution of the interaction of a new chemical entity, eflucimibe, with gamma-cyclodextrin during kneading process. Eur J Pharm Sci 23:123–129

    Article  CAS  PubMed  Google Scholar 

  • Goke K, Bunjes H (2017) Drug solubility in lipid nanocarriers: Influence of lipid matrix and available interfacial area. Int J Pharm 529:617–628

    Article  CAS  PubMed  Google Scholar 

  • Han S-M, Na Y-G, Lee H-S, Son G-H, Jeon S-H et al (2018) Improvement of cellular uptake of hydrophilic molecule, calcein, formulated by liposome. J Pharm Investig 48:595–601

    Article  CAS  Google Scholar 

  • He J, Liu Y, Zhu T, Zhu J, Dimeco F et al (2012) CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteom 11:M111 010744

    Article  CAS  Google Scholar 

  • Kim J, Tang JY, Gong R, Kim J, Lee JJ et al (2010) Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17:388–399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lang B, Liu S, McGinity JW, Williams RO 3rd (2016) Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions. Drug Dev Ind Pharm 42:429–445

    Article  CAS  PubMed  Google Scholar 

  • Liu R, Li J, Zhang T, Zou L, Chen Y et al (2014) Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy 10:1241–1255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K et al (1998) P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 42:1738–1744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO (2011) The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem 286:44045–44056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B (2014) Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol 32:32–45

    Article  CAS  PubMed  Google Scholar 

  • Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25:1–7

    Article  PubMed  Google Scholar 

  • Parikh T, Sandhu HK, Talele TT, Serajuddin AT (2016) Characterization of solid dispersion of itraconazole prepared by solubilization in concentrated aqueous solutions of weak organic acids and drying. Pharm Res 33:1456–1471

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253–1265

    Article  CAS  PubMed  Google Scholar 

  • Sayed S, Elsayed I, Ismail MM (2018) Optimization of beta-cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug. Int J Pharm 549:249–260

    Article  CAS  PubMed  Google Scholar 

  • Seo J, Kim M-J, Jeon S-O, Oh D-H, Yoon K-H et al (2018) Enhanced topical delivery of fish scale collagen employing negatively surface-modified nanoliposome. J Pharm Investig 48:243–250

    Article  CAS  Google Scholar 

  • Shin DH, Xuan S, Kim W-Y, Bae G-U, Kim J-S (2014) CD133 antibody-conjugated immunoliposomes encapsulating gemcitabine for targeting glioblastoma stem cells. J Mater Chem B 2:3771–3781

    Article  CAS  Google Scholar 

  • Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401

    Article  CAS  PubMed  Google Scholar 

  • Stevens DA (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy 19:603–611

    Article  CAS  PubMed  Google Scholar 

  • Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160

    Article  CAS  PubMed  Google Scholar 

  • Vieira DB, Gamarra LF (2016) Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomed 11:5381–5414

    Article  CAS  Google Scholar 

  • Xuan S, Shin DH, Kim J-S (2014) Angiopep-2-conjugated liposomes encapsulating γ-secretase inhibitor for targeting glioblastoma stem cells. J Pharm Investig 44:473–483

    Article  CAS  Google Scholar 

  • Zhang L, Zhang Q, Wang X, Zhang W, Lin C et al (2015) Drug-in-cyclodextrin-in-liposomes: a novel drug delivery system for flurbiprofen. Int J Pharm 492:40–45

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2017R1D1A1B03030849) and the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST, No.2011-0030074).

Author information

Authors and Affiliations

  1. Drug Information Research Institute (DIRI), College of Pharmacy, Sookmyung Women’s University, Seoul, 04310, South Korea

    Sung-Won Yoon & Jin-Seok Kim

  2. College of Pharmacy, Chungbuk National University, Cheongju, 28160, South Korea

    Dae Hwan Shin

Authors
  1. Sung-Won Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dae Hwan Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin-Seok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-Seok Kim.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoon, SW., Shin, D.H. & Kim, JS. Liposomal itraconazole formulation for the treatment of glioblastoma using inclusion complex with HP-β-CD. J. Pharm. Investig. 49, 477–483 (2019). https://doi.org/10.1007/s40005-019-00432-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-019-00432-4

Keywords

Search

Navigation